BRAINS INNER WORKINGS – A NIMH CURRICULUM NOW AVAILABLE ONLINE
Components on Brains Inner Workings, NIMH’s student curriculum, are now available online. The teacher’s and student’s manual, as well as the videos are available online:
http://www.nimh.nih.gov/health/brains-inner-workings/the-brains-inner-workings-activities-for-grades-9-through-12.shtml
CLINICAL TRIALS UDATE
Find Clinical Trials by State:
http://www.clinicaltrials.gov/ct2/results/map/click?term=Behaviors+and+Mental+Disorders%5BCONDITION-BROWSE-BRANCH%5D&recr=Open&fund=01&map.x=163&map.y=177
NIMH: Major Depression (Adult) Research Study
If you (or someone you know) have been diagnosed with major depression, you may be able to participate in a National Institute of Mental Health research study investigating a novel medication. This treatment study is studying if a research medication can produce a rapid reduction of depressive symptoms in patients with treatment-resistant major depressive disorder. This 7-week inpatient study is conducted at the NIH?Clinical Center in Bethesda, Maryland, and compares the medication to a placebo (inactive salt solution). If you are 18-65 years of age and have been diagnosed with major depression and have taken two antidepressants that did not help, you may be eligible for this clinical trial. Research evaluations and medications are provided at no cost. Transportation reimbursement is covered from anywhere in the United States. To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644)(TTY: 1-866-411-1010) or moodresearch@mail.nih.gov
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov
NIMH: Bipolar Disorder (Adult) Research Study
Antidepressant (Rapid) Effects of Ketamine
If you (or someone you know) have been diagnosed with bipolar disorder, you may be able to participate in a trial designed to understand the causes of depression and rapid antidepressant response. Specifically, we are testing whether ketamine, a drug that affects glutamate in the brain will improve symptoms of depression within a matter of hours. If you are 18-65 years of age and have been diagnosed with bipolar disorder and previously failed to respond to treatment, you may be eligible for an inpatient trial designed to bring about a rapid antidepressant effect. After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and we will cover all transportation costs from anywhere in the United States. Compensation is provided for study procedures. To find out if you qualify or for more information, please call 1-877-MIND-NIH (1-877-646-3644) or email us at moodresearch@mail.nih.gov
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click here http://patientinfo.nimh.nih.gov
NIMH: Clinical Trial of Citalopram and Methylphenidate in Severe Mood Dysregulation
This study is testing the effectiveness of methylphenidate plus citalopram vs. methylphenidate plus placebo for decreasing irritability in children with severe mood dysregulation (SMD). Children with SMD display chronic anger, sadness, or irritability, as well as hyperarousal (such as insomnia, distractibility, hyperactivity) and extreme responses to frustration (such as frequent, severe temper tantrums).
Children ages seven to 17 with SMD may be eligible to participate in this 12-
to 15-week inpatient or outpatient study. This study has four phases:
· During Phase I participants are gradually withdrawn from all current psychotropic medications.
· Phase II is a one-week psychotropic medication-free period.
· During Phase III, which lasts two weeks, participants are treated with methylphenidate alone.
· Phase IV lasts for eight weeks. During this time, participants continue methylphenidate treatment and are randomly assigned to also receive either citalopram or placebo.
At the end of the study, those who received methylphenidate plus placebo will have the opportunity to receive methylphenidate plus active citalopram if clinically appropriate.
All procedures and medications associated with the research are provided at no cost to participants, and transportation expenses are reimbursed by NIMH. Schooling will be provided while on the inpatient unit or in day treatment. For more information, please call (301) 496-8381 or send an email to bipolarkids@mail.nih.gov.
Clinical Trial of Riluzole in Pediatric Bipolar Disorder
This study is testing the effectiveness of riluzole versus placebo for decreasing anxiety in children with pediatric bipolar disorder (BP). Children and youth with BP display episodic elevated mood and associated symptoms of decreased need for sleep, increased goal-directed behavior, and increased self-esteem/grandiosity. Children ages nine to 17 with BP may be eligible to participate in this 12- to 15-week inpatient or outpatient study. This study has four phases. During Phase I, participants are gradually withdrawn from all current psychotropic medications. Phase II is a one-week medication-free period. During Phase III, which lasts two weeks, participants are randomly assigned to receive either riluzole or placebo (a "sugar pill"). Phase IV lasts for six weeks. During this time, participants continue riluzole or placebo. At the end of the study, those who received placebo have the opportunity to receive riluzole. All procedures and medications associated with the research are provided at no cost to participants, and assistance with transportation and lodging expenses is available. Schooling will be provided while on the inpatient unit or in day treatment. To determine eligibility or for more information, please call (301) 496-8381 or email us at bipolarkids@mail.nih.gov .
For more information on Mental Health Research Studies conducted by NIMH http://patientinfo.nimh.nih.gov